The Hanover Insurance Group, Inc. (THG) At $119.15 Forms Top; Seattle Genetics (SGEN) Has 1.23 Sentiment

The Hanover Insurance Group, Inc. (NYSE:THG) Logo

The Hanover Insurance Group, Inc. (THG) formed multiple top with $128.68 target or 8.00% above today’s $119.15 share price. The Hanover Insurance Group, Inc. (THG) has $5.07 billion valuation. The stock increased 0.24% or $0.28 during the last trading session, reaching $119.15. About 14,139 shares traded. The Hanover Insurance Group, Inc. (NYSE:THG) has risen 27.09% since May 17, 2017 and is uptrending. It has outperformed by 15.54% the S&P500.

Seattle Genetics Inc (SGEN) investors sentiment increased to 1.23 in 2017 Q4. It’s up 0.45, from 0.78 in 2017Q3. The ratio is positive, as 112 active investment managers increased and opened new positions, while 91 sold and decreased their holdings in Seattle Genetics Inc. The active investment managers in our database now have: 141.83 million shares, up from 140.23 million shares in 2017Q3. Also, the number of active investment managers holding Seattle Genetics Inc in top ten positions decreased from 3 to 2 for a decrease of 1. Sold All: 24 Reduced: 67 Increased: 68 New Position: 44.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $9.16 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Baker Bros. Advisors Lp holds 21.2% of its portfolio in Seattle Genetics, Inc. for 45.73 million shares. Lagoda Investment Management L.P. owns 306,576 shares or 6.25% of their US portfolio. Moreover, Redmile Group Llc has 2.7% invested in the company for 1.16 million shares. The New York-based Opus Point Partners Management Llc has invested 1.65% in the stock. Eventide Asset Management Llc, a Massachusetts-based fund reported 525,000 shares.

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on July, 26. They expect $-0.36 EPS, up 7.69% or $0.03 from last year’s $-0.39 per share. After $-0.61 actual EPS reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts -40.98% EPS growth.

Since January 1, 0001, it had 3 insider purchases, and 10 insider sales for $268.25 million activity.

The stock decreased 0.99% or $0.58 during the last trading session, reaching $57.92. About 175,980 shares traded. Seattle Genetics, Inc. (SGEN) has declined 20.48% since May 17, 2017 and is downtrending. It has underperformed by 32.03% the S&P500.

Ratings analysis reveals 40% of Seattle Genetics’s analysts are positive. Out of 5 Wall Street analysts rating Seattle Genetics, 2 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. SGEN was included in 5 notes of analysts from September 7, 2016. The firm has “Underperform” rating by Bank of America given on Friday, February 10. The stock has “Outperform” rating by RBC Capital Markets on Monday, October 10. On Wednesday, September 7 the stock rating was initiated by Morgan Stanley with “Overweight”. The firm has “Neutral” rating by Goldman Sachs given on Thursday, September 15. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Neutral” rating given on Monday, December 12 by Credit Suisse.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Seekingalpha.com which released: “Seattle Genetics Fairly Valued, Pending Data” on May 14, 2018, also Streetinsider.com with their article: “Seattle Genetics (SGEN) Announces Data Presentations at ASCO” published on May 17, 2018, Businesswire.com published: “Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting” on May 17, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Seekingalpha.com and their article: “Seattle Genetics (SGEN) Q1 2018 Results – Earnings Call Transcript” published on April 27, 2018 as well as Digitaljournal.com‘s news article titled: “Seattle Genetics Appoints Roger D. Dansey, MD, Chief Medical Officer” with publication date: May 17, 2018.

Among 5 analysts covering Hanover Insurance Group (NYSE:THG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Hanover Insurance Group has $13300 highest and $86 lowest target. $106.75’s average target is -10.41% below currents $119.15 stock price. Hanover Insurance Group had 17 analyst reports since August 15, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by Wood given on Thursday, May 18. The stock has “Buy” rating by Sandler O’Neill on Friday, April 6. The firm has “Buy” rating given on Saturday, August 15 by Zacks. Sandler O’Neill maintained The Hanover Insurance Group, Inc. (NYSE:THG) on Tuesday, April 17 with “Buy” rating. Keefe Bruyette & Woods maintained the shares of THG in report on Thursday, February 1 with “Hold” rating. The stock of The Hanover Insurance Group, Inc. (NYSE:THG) has “Hold” rating given on Friday, August 4 by Keefe Bruyette & Woods. As per Monday, December 4, the company rating was maintained by Keefe Bruyette & Woods. The stock of The Hanover Insurance Group, Inc. (NYSE:THG) earned “Buy” rating by Sandler O’Neill on Tuesday, January 9. The firm earned “Hold” rating on Thursday, November 2 by Keefe Bruyette & Woods. The firm has “Outperform” rating by BMO Capital Markets given on Monday, March 28.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart